FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4297776369> ?p ?o ?g. }

• W4297776369 endingPage "S21" @default.
• W4297776369 startingPage "S20" @default.
• W4297776369 abstract "Objectives: The ovarian cancer (OC) treatment (tx) landscape has evolved with recent approvals from the FDA and EMA for several novel tx regimens, including first-line maintenance (1Lm) therapies. The antiangiogenic agent (VEGF inhibitor [VEGFi]) bevacizumab (bev) was the first 1Lm tx to be approved for advanced OC (Dec 2011 EMA; June 2018 FDA), followed by the PARPi olaparib (Dec 2018 FDA; June 2019 EMA), PARPi niraparib (Apr 2020 FDA; Oct 2020 EMA), and olaparib + bev (May 2020 FDA; Nov 2020 EMA). There is currently a lack of real-world data evaluating the impact of these approvals on the OC tx paradigm. This analysis describes patient (pt) characteristics, biomarker testing rates, and tx patterns for pts diagnosed with advanced OC in Europe and the US, with a focus on 1Lm. Methods: A retrospective chart review study of electronic medical records (EMRs) in Italy (IT), France (FR), Germany (DE), Spain, the UK, and the US was conducted for pts diagnosed with OC between Jun 1, 2017, and May 31, 2020. The study was conducted in line with Healthcare Market Research guidelines. Data were extracted by oncologists from EMRs to pt record forms (PRFs) and descriptively summarized. Pts with advanced (stage III/IV) disease were stratified by country and diagnosis date to provide information on tx patterns at different tx lines (Cohort 1: Jun 1, 2017-May 31, 2018; Cohort 2: Jun 1, 2018-May 31, 2019; and Cohort 3: Jun 1, 2019-May 31, 2020). Results: Overall, 416 oncologists completed PRFs for 7072 pts; 5386 pts had stage III/IV disease (Table). In total, 79.3%, 83.3%, and 84.7% of pts were tested for BRCA mutations or homologous recombination deficiency in Cohorts 1, 2, and 3, respectively. Of pts who received primary tx, 53.0%, 60.5%, and 65.8% received 1Lm in Cohorts 1, 2, and 3, respectively; the remainder received active surveillance. Use of 1Lm was highest in FR (71.5%; 710/993) and lowest in the UK (47.8%; 339/709). The number of pts receiving 1Lm increased (Cohort 1 vs 3) in all countries except DE. In Cohorts 1, 2, and 3, 81.6%, 73.2%, and 57.1% of pts received VEGFi monotherapy (mono), respectively; 11.9%, 20.9%, and 35.0% received PARPi mono; 2.3%, 3.5%, and 4.5% received PARPi + VEGFi tx; and 4.2%, 2.4%, and 3.4% received chemotherapy or other agents. For all cohorts combined, use of 1Lm PARPi mono was numerically highest in the US (40.0%; 174/435) and lowest in FR (12.0%; 85/710); VEGFi mono use was highest in FR (84.8%; 602/710) and lowest in the US (42.8%; 186/435). Funding: GlaxoSmithKline study (OneCDP#214555). Objectives: The ovarian cancer (OC) treatment (tx) landscape has evolved with recent approvals from the FDA and EMA for several novel tx regimens, including first-line maintenance (1Lm) therapies. The antiangiogenic agent (VEGF inhibitor [VEGFi]) bevacizumab (bev) was the first 1Lm tx to be approved for advanced OC (Dec 2011 EMA; June 2018 FDA), followed by the PARPi olaparib (Dec 2018 FDA; June 2019 EMA), PARPi niraparib (Apr 2020 FDA; Oct 2020 EMA), and olaparib + bev (May 2020 FDA; Nov 2020 EMA). There is currently a lack of real-world data evaluating the impact of these approvals on the OC tx paradigm. This analysis describes patient (pt) characteristics, biomarker testing rates, and tx patterns for pts diagnosed with advanced OC in Europe and the US, with a focus on 1Lm. Methods: A retrospective chart review study of electronic medical records (EMRs) in Italy (IT), France (FR), Germany (DE), Spain, the UK, and the US was conducted for pts diagnosed with OC between Jun 1, 2017, and May 31, 2020. The study was conducted in line with Healthcare Market Research guidelines. Data were extracted by oncologists from EMRs to pt record forms (PRFs) and descriptively summarized. Pts with advanced (stage III/IV) disease were stratified by country and diagnosis date to provide information on tx patterns at different tx lines (Cohort 1: Jun 1, 2017-May 31, 2018; Cohort 2: Jun 1, 2018-May 31, 2019; and Cohort 3: Jun 1, 2019-May 31, 2020). Results: Overall, 416 oncologists completed PRFs for 7072 pts; 5386 pts had stage III/IV disease (Table). In total, 79.3%, 83.3%, and 84.7% of pts were tested for BRCA mutations or homologous recombination deficiency in Cohorts 1, 2, and 3, respectively. Of pts who received primary tx, 53.0%, 60.5%, and 65.8% received 1Lm in Cohorts 1, 2, and 3, respectively; the remainder received active surveillance. Use of 1Lm was highest in FR (71.5%; 710/993) and lowest in the UK (47.8%; 339/709). The number of pts receiving 1Lm increased (Cohort 1 vs 3) in all countries except DE. In Cohorts 1, 2, and 3, 81.6%, 73.2%, and 57.1% of pts received VEGFi monotherapy (mono), respectively; 11.9%, 20.9%, and 35.0% received PARPi mono; 2.3%, 3.5%, and 4.5% received PARPi + VEGFi tx; and 4.2%, 2.4%, and 3.4% received chemotherapy or other agents. For all cohorts combined, use of 1Lm PARPi mono was numerically highest in the US (40.0%; 174/435) and lowest in FR (12.0%; 85/710); VEGFi mono use was highest in FR (84.8%; 602/710) and lowest in the US (42.8%; 186/435). Funding: GlaxoSmithKline study (OneCDP#214555)." @default.
• W4297776369 created "2022-10-01" @default.
• W4297776369 creator A5009351129 @default.
• W4297776369 creator A5028815015 @default.
• W4297776369 creator A5032950594 @default.
• W4297776369 creator A5033345462 @default.
• W4297776369 creator A5043767642 @default.
• W4297776369 creator A5046044343 @default.
• W4297776369 creator A5050590164 @default.
• W4297776369 creator A5052917768 @default.
• W4297776369 creator A5079485962 @default.
• W4297776369 creator A5079842256 @default.
• W4297776369 creator A5082530577 @default.
• W4297776369 creator A5083659627 @default.
• W4297776369 date "2022-08-01" @default.
• W4297776369 modified "2023-10-18" @default.
• W4297776369 title "Evolution of the Ovarian Cancer Treatment Paradigm, Including Maintenance Treatment, in the US and Europe: A Real-World Chart Review Analysis (2017-2020) (028)" @default.
• W4297776369 doi "https://doi.org/10.1016/s0090-8258(22)01246-x" @default.
• W4297776369 hasPublicationYear "2022" @default.
• W4297776369 type Work @default.
• W4297776369 citedByCount "2" @default.
• W4297776369 countsByYear W42977763692022 @default.
• W4297776369 countsByYear W42977763692023 @default.
• W4297776369 crossrefType "journal-article" @default.
• W4297776369 hasAuthorship W4297776369A5009351129 @default.
• W4297776369 hasAuthorship W4297776369A5028815015 @default.
• W4297776369 hasAuthorship W4297776369A5032950594 @default.
• W4297776369 hasAuthorship W4297776369A5033345462 @default.
• W4297776369 hasAuthorship W4297776369A5043767642 @default.
• W4297776369 hasAuthorship W4297776369A5046044343 @default.
• W4297776369 hasAuthorship W4297776369A5050590164 @default.
• W4297776369 hasAuthorship W4297776369A5052917768 @default.
• W4297776369 hasAuthorship W4297776369A5079485962 @default.
• W4297776369 hasAuthorship W4297776369A5079842256 @default.
• W4297776369 hasAuthorship W4297776369A5082530577 @default.
• W4297776369 hasAuthorship W4297776369A5083659627 @default.
• W4297776369 hasConcept C104317684 @default.
• W4297776369 hasConcept C121608353 @default.
• W4297776369 hasConcept C126322002 @default.
• W4297776369 hasConcept C143998085 @default.
• W4297776369 hasConcept C182979987 @default.
• W4297776369 hasConcept C185592680 @default.
• W4297776369 hasConcept C2776694085 @default.
• W4297776369 hasConcept C2777802072 @default.
• W4297776369 hasConcept C2779962180 @default.
• W4297776369 hasConcept C2780427987 @default.
• W4297776369 hasConcept C55493867 @default.
• W4297776369 hasConcept C71924100 @default.
• W4297776369 hasConcept C72563966 @default.
• W4297776369 hasConcept C82381507 @default.
• W4297776369 hasConceptScore W4297776369C104317684 @default.
• W4297776369 hasConceptScore W4297776369C121608353 @default.
• W4297776369 hasConceptScore W4297776369C126322002 @default.
• W4297776369 hasConceptScore W4297776369C143998085 @default.
• W4297776369 hasConceptScore W4297776369C182979987 @default.
• W4297776369 hasConceptScore W4297776369C185592680 @default.
• W4297776369 hasConceptScore W4297776369C2776694085 @default.
• W4297776369 hasConceptScore W4297776369C2777802072 @default.
• W4297776369 hasConceptScore W4297776369C2779962180 @default.
• W4297776369 hasConceptScore W4297776369C2780427987 @default.
• W4297776369 hasConceptScore W4297776369C55493867 @default.
• W4297776369 hasConceptScore W4297776369C71924100 @default.
• W4297776369 hasConceptScore W4297776369C72563966 @default.
• W4297776369 hasConceptScore W4297776369C82381507 @default.
• W4297776369 hasLocation W42977763691 @default.
• W4297776369 hasOpenAccess W4297776369 @default.
• W4297776369 hasPrimaryLocation W42977763691 @default.
• W4297776369 hasRelatedWork W1981860337 @default.
• W4297776369 hasRelatedWork W2057087136 @default.
• W4297776369 hasRelatedWork W2950446512 @default.
• W4297776369 hasRelatedWork W2994977341 @default.
• W4297776369 hasRelatedWork W3015072749 @default.
• W4297776369 hasRelatedWork W3040348061 @default.
• W4297776369 hasRelatedWork W3090114554 @default.
• W4297776369 hasRelatedWork W3113307403 @default.
• W4297776369 hasRelatedWork W3204368990 @default.
• W4297776369 hasRelatedWork W4283025800 @default.
• W4297776369 hasVolume "166" @default.
• W4297776369 isParatext "false" @default.
• W4297776369 isRetracted "false" @default.
• W4297776369 workType "article" @default.